The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients

Gynecologic Oncology

Volumn 115, Issue 3, 2009, Pages 343-348

  Vernooij, Flora ^a   Witteveen, Petronella O ^a   Verweij, Eva ^a   van der Graaf, Yolanda ^a   Heintz, A Peter M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chemotherapy, adjuvant; Hospitals; Medical Oncology; Netherlands; Ovarian Neoplasm; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; HOSPITALS; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70350567249     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.08.018     Document Type: Article

References (17)

1. Wolfe C.D., Tilling K., and Raju K.S. Management and survival of ovarian cancer patients in south east England. Eur. J. Cancer 33 (1997) 1835-1840
2. Tingulstad S., Skjeldestad F.E., and Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet. Gynecol. 102 (2003) 499-505
3. Paulsen T., Kjaerheim K., Kaern J., Tretli S., and Tropé C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int. J. Gynecol. Cancer 16 Suppl 1 (2006) 11-17
4. Schrag D., Earle C., Xu F., et al. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J. Natl. Cancer Inst. 98 (2006) 163-171
5. Vernooij F., Heintz P., Witteveen E., et al. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol. Oncol. 105 (2007) 801-812
6. Junor E.J., Hole D.J., McNulty L., Mason M., and Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br. J. Obstet. Gynaecol. 106 (1999) 1130-1136
7. Engelen M.J., Kos H.E., Willemse P.H., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106 (2006) 589-598
8. Silber J.H., Rosenbaum P.R., Polsky D., et al. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?. J. Clin. Oncol. 25 (2007) 1169-1175
9. Vernooij F., Heintz A.P.M., Witteveen P.O., et al. Specialized care and survival of ovarian cancer patients in the Netherlands: nationwide cohort study. J. Natl. Cancer Inst. 100 (2008) 1-9
10. Vernooij F., Heintz A.P.M., Coebergh J.W., et al. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol. Oncol. 112 (2009) 455-461
11. Maas H.A., Kruitwagen R.F., Lemmens V.E., Goey S.H., and Janssen-Heijnen M.L. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol. Oncol. 97 (2005) 104-109
12. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 40 (1987) 373-383
13. Burton A., and Altman D.G. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br. J. Cancer 91 (2004) 4-8
14. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
15. Gronlund B., Høgdall C., Hansen H.H., and Engelholm S.A. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 94 (2002) 1961-1967
16. Carey M.S., Bacon M., Tu D., et al. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol. Oncol. 108 (2008) 100-105
17. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43